To study which EGFR‐related signaling pathways regulate CD274 expression in NSCLC without targetable genetic alterations, we collected RNA sequencing data of 159 lung adenocarcinoma and 166 squamous cell lung carcinoma samples from TCGA, excluding samples with driver mutations in EGFR, ALK, BRAF, ROS1, MET, ERBB2 and RET. Activating KRAS mutations were present in 75 of the lung adenocarcinoma and in one of the squamous cell carcinoma samples. This evidence concerns the gene EGFR and non-small cell lung carcinoma.